NCT03764462View on ClinicalTrials.gov

Evaluating the Pharmacokinetic Characteristics of AD-101 in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

December 14, 2018

Primary Completion Date

January 2, 2019

Study Completion Date

February 8, 2019

Conditions
Osteoporosis
Interventions
DRUG

AD-101 45mg

Raloxifene 45mg tablet

DRUG

Raloxifene 60mg

Raloxifene 60mg tablet

Trial Locations (1)

41944

Kyungpook National University Hospital, Daegu

All Listed Sponsors
lead

Addpharma Inc.

INDUSTRY

NCT03764462 - Evaluating the Pharmacokinetic Characteristics of AD-101 in Healthy Volunteers | Biotech Hunter | Biotech Hunter